Disclosures

Al Benson III MD, FACP, FASCO

Professor, Medicine, Hematology Oncology Division; Feinberg School of Medicine; Director for Cooperative Groups at the Robert H. Lurie Comprehensive Cancer Center

Received clinical research support/data safety monitoring board from Acerta Pharma, Amgen Inc., Astellas Pharma US, Inc., Bristol-Myers Squibb Company, Celgene Corporation, Infinity Pharmaceuticals, Inc., MedImmune Inc., Merck & Co., Inc., Novartis Pharmaceuticals Corporation, and Taiho Pharmaceuticals Co., Ltd.

Served on scientific advisory board or as a consultant or expert witness for Astellas Pharma US, Inc., Bayer HealthCare, Bristol-Myers Squibb Company, Genentech, Inc., Merck & Co., Inc., Purdue Pharma LP, and Taiho Pharmaceuticals Co., Ltd.

Jennifer R. Brown, MD, PhD

Associate Professor of Medicine, Dana-Farber Cancer Institute

Received clinical research support/data safety monitoring board from Invectys and MorphoSys AG.

Served on scientific advisory board or as a consultant or expert witness for AbbVie, Inc., Acerta Pharma, AstraZeneca Pharmaceuticals LP, BeiGene, Celgene Corporation, Novartis Pharmaceuticals Corporation, Sunesis Pharmaceuticals, Inc., and Verastem.

Daniel G. Coit, MD

Surgical Oncologist, Memorial Sloan Kettering Cancer Center, New York

Reported no conflicts of interest.

David S. Ettinger, MD

Alex Grass Professor of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

Received clinical research support/data safety monitoring board from Golden Biotechnology.

Served on scientific advisory board or as a consultant or expert witness for Alkemes, Inc., AstraZeneca Pharmaceuticals LP, BeyondSpring Pharmaceuticals, Bristol-Myers Squibb Company, and Guardant Health, Inc.

William J. Gradishar, MD

Director, Clinical Network; Chief, Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago

Received clinical research support/data safety monitoring board from Genentech, Inc. and Seattle Genetics, Inc.

Served on scientific advisory board or as a consultant or expert witness for Abbott Laboratories, AstroZeneca Pharmaceuticals LP, Genentech, Inc., Merck & Co., Inc., and Pfizer Inc.

Served as a promotional advisor or on speakers bureau for Seattle Genetics, Inc.

Robert I Haddad, MD

Chief, Division of Head and Neck Oncology and Institute Physician, Dana-Farber Cancer Institute; Professor of Medicine, Harvard Medical School

Received clinical research support/data safety monitoring board from Bristol-Meyers Squibb Company, Genentech, Inc., Isa Therapeutics, Kura Oncology, Inc., Merck & Co., Inc., Nanobiotix, and Pfizer Inc.

Served on scientific advisory board or as a consultant or expert witness for Bayer HealthCare, Bristol-Myers Squibb Company, Eisai Inc., Genentech, Inc., GlaxoSmithKline, Glenmark, Immunomic Therapeutics, Loxo, Merck & Co., Inc., Nanobiotix, and Pfizer Inc.

Gabriela Hobbs, MD

Clinical Director, Leukemia Service at Massachusetts General Hospital

Received clinical research support/data safety monitoring board from Bayer HealthCare, Incyte Corporation, and Merck & Co., Inc.

Served on scientific advisory board or as a consultant or expert witness for Agios, Inc., Celgene Corporation, Incyte Corporation, and Jazz Pharmaceuticals Inc.

Prashant Kapoor, MD

Assistant Professor of Medicine and Oncology (Division of Hematology), Mayo Clinic, Rochester, Minnesota

Received clinical research support/data safety monitoring board from Takeda Pharmaceuticals North America, Inc., Amgen, Inc., AbbVie, GlaxoSmithKline, Janssen Pharmaceutica Products, LP., and Sanofi-aventis U.S.

Served on scientific advisory board or as a consultant or expert witness for Sanofi-aventis U.S., GlaxoSmithKline, Takeda Pharmaceuticals North America, Inc. with compensation to Mayo Clinic.

Has received personal compensation from Pharmacyclics, Cellectar and Karyopharm for serving on scientific advisory board or as a consultant.

Involved in the development of Mayo Clinic mSMART guidelines.

Shaji K. Kumar, MD

Professor of Medicine, Mayo Clinic, Rochester, Minnesota

Received clinical research support/data safety monitoring board from AbbVie, Inc., Allogene, Amgen Inc., Bristol-Myers Squibb Company, Carsgen, Janssen Pharmaceutica Products, LP, Kite Pharma, MedImmune Inc., Merck & Co., Inc., Roche Laboratories, Inc., Sanofi-Aventis U.S., Takeda Pharmaceuticals North America, Inc., and Tenebio.

Served on scientific advisory board or as a consultant or expert witness for AbbVie, Inc., Amgen Inc., Celgene Corporation, Cellectar, Genecentrix, GlaxoSmithKline, Jannsen Pharmaceutica Products, LP, Molecular Partners, Oncopeptides, Roche Laboratories, Inc., Sanofi-Aventis U.S, and Takeda Pharmaceuticals North America, Inc.

Karl D. Lewis, MD

Associate Professor, Division of Medical Oncology, University of Colorado Denver School of Medicine

Received clinical research support from or served on data safety monitoring board for Array, Bristol-Myers Squibb Company, Incyte Corporation, Iovance, Kartos, Merck & Co., Inc., Nektar Therapeutics, Neon, Regeneron Pharmaceuticals, Inc., and Roche Laboratories, Inc.

Served on scientific advisory board or as a consultant or expert witness for Genentech, Inc., Merck & Co., Inc., and Regeneron Pharmaceuticals, Inc.

Ursula A. Matulonis, MD

Professor of Medicine, Harvard Medical School; Director, Gynecologic Oncology; Brock-Wilson Family Chair, Dana-Farber Cancer Institute, Boston

Served on scientific advisory board or as a consultant or expert witness for 2X Oncology, AstraZeneca, Clovis, Fujifilm, Geneos, Myriad Genetic Laboratories, Syntax, and Tesaro.

Michael J. Mauro, MD

Leader, Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, New York

Received clinical research support from or served on data safety monitoring board as principal investigator for Novartis Pharmaceuticals Corporation.

Served on scientific advisory board or as a consultant or expert witness for Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation, Takeda Pharmaceuticals North America, Inc., and Pfizer, Inc.

James L. Mohler, MD

Associate Director and Senior Vice President of Translational Research; Chief, Inter-Institutional Academics; Professor of Oncology, Roswell Park Comprehensive Cancer Center

Reported no conflicts of interest.

Robert J. Motzer, MD

Jack and Dorothy Byrne Chair in Clinical Oncology, Memorial Sloan Kettering Cancer Center, New York

Received clinical research support from or served on data safety monitoring board for Bristol-Myers Squibb Company, Eisai Inc., Exelixis Inc., Genentech, Inc., and Pfizer, Inc.

Served as a consultant for Eli Lilly and Company, Genentech, Inc., Merck & Co., Inc., and Pfizer Inc. 

Rebecca Olin, MD, MS

Associate Professor, Department of Medicine (Hematology/Oncology), UCSF

Received clinical research support from or served on data safety monitoring board for Astellas Pharma US, Inc., Daiichi-Sankyo Co., Genetech, Inc., and Pfizer Inc.

Served on scientific advisory board or as a consultant or expert witness for Amgen Inc., Genentech, Inc., and Jazz Pharmaceuticals Inc.

David G. Pfister, MD

Medical Oncologist, Memorial Sloan Kettering Cancer Center, New York

Received clinical research support from or served on data safety monitoring board for AstraZeneca Pharmaceuticals LP, Atara, Bayer HealthCare, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eisai Inc., Eli Lilly and Company, Exelixis Inc., Genentech, Inc., GlaxoSmithKline, Hookipa, Incyte Corporation, Kura Oncology, Inc., MedImmune Inc., Meira, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., Plexxikon, and Regeneron Pharmaceuticals, Inc.

Served on scientific advisory board or as a consultant or expert witness for Bristol-Meyers Squibb Company, Celgene Corporation, Incyte Corporation, and Merck & Co., Inc.

Michael A. Postow, MD

Medical Oncologist, Memorial Sloan Kettering Cancer Center, New York

Received clinical research support from or served on data safety monitoring board for Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation, Array BioPharma, Infinity Pharmaceuticals, and Rgenix, Inc.

Served on scientific advisory board or as a consultant or expert witness for Bristol-Myers Squibb Company, Array BioPharma, Merck & Co., Inc., Incyte Corporation, and Newlink Genetics.

Received honoraria from Merck and Bristol-Myers Squibb Company.

Sandy Srinivas, MD

Professor of Medicine, Stanford University Medical Center

Has received clinical research support from or served on a data safety monitoring board for Bayer HealthCare, Clovis Oncology, Exelixis Inc., Janssen Pharmaceutica Products, LP, and Pfizer Inc.

Served on scientific advisory board or as a consultant or expert witness for Bayer HealthCare, Clovis Oncology, and Janssen Pharmaceutica Products, LP.

Vatche Tchekmedyian, MD

Hematologist and Oncologist, Maine Medical Center, Portland, ME

Holds stock in Infinity Pharmaceuticals, Inc., Halozyme Therapeutics, Inc., Global Blood Therapeutics, Portola Pharmaceuticals, Inc., Rigel Pharmaceuticals, Inc., and BioMarin Pharmaceutical

Medical Writers:

Nahae Kim, MPH

Serves as Assistant Research Coordinator for Northwell Health.

The following medical writers contributing to JNCCN 360 reported no conflicts of interest:

Sarah Campen, PharmD; Cordi Craig; Joseph Cupolo; Celeste L. Dixon;  Dana A. Elya, MS, RD, CDN; Joseph Fanelli; Melissa E. Fryman, MS; Lauren Harrison, MS; Kelly M. Hennessey, PhD; Susan London; Margie Miller; Anna Nowogrodzki; Hillary Ojeda; Susan Reckling; Kayci Reyer; Max J. Rosenthal; Joshua Swore and Sara Tewksbury